The debate over marijuana has long been a tug-of-war between those pushing for full federal legalization and others worried about issues like stinky streets, psychological damage, and lazy teenagers (and others) puffing away on skunk. But as President Trump indicated last year, the rescheduling of marijuana from a Schedule I to a Schedule III drug actually offers a sensible middle ground that addresses concerns on both sides.
Right now, marijuana’s classification as a Schedule I substance means it’s considered to have no accepted medical use and a high potential for abuse, which is hampering research efforts into the plant. Moving it to Schedule III would acknowledge its medical benefits, allowing scientists to study its therapeutic potential. This could very well lead to new treatments and a better understanding of how medical cannabis can help patients.
For veterans, as an example, dealing with chronic pain or PTSD, medical marijuana has already shown promise as a treatment option. Federal restrictions can make it difficult for them to access cannabis-based therapies, but rescheduling enables veterans to discuss and consider medical marijuana with healthcare providers without legal ramifications.
Cannabis businesses also face hefty tax burdens due to marijuana’s Schedule I status, which prevents them from claiming standard business deductions under Section 280E of the Internal Revenue Code. Reclassification would lift these penalties, allowing businesses to deduct ordinary expenses and operate on a more level playing field.
Former President Donald Trump has expressed support for rescheduling marijuana, emphasizing the need to end unnecessary arrests and promote research.
“As I have previously stated, I believe it is time to end needless arrests and incarcerations of adults for small amounts of marijuana for personal use. We must also implement smart regulations, while providing access for adults, to safe, tested product. As a Floridian, I will be voting YES on Amendment 3 this November. As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens.”
– President Donald J. Trump, 2024.
Over 10 million patients across more than 40 states rely on medical marijuana for various health conditions. The current disconnect between federal and state laws creates confusion and potential legal risks for these individuals.
Concerns about public safety, such as fears of increased street use and its impact on youth, are valid. Rescheduling allows for the implementation of stringent regulations and quality controls, ensuring that cannabis products are safe and access is restricted.
Trump’s endorsement highlights a growing consensus that rescheduling is a practical step forward, balancing the need for reform with appropriate safeguards.
This policy shift addresses critical issues in a practical and compassionate manner by facilitating medical research, supporting veterans, rectifying tax inequities, stimulating economic growth, clarifying legal ambiguities for patients, and enhancing public safety through regulation. It’s a move toward a more sensible and fair approach to cannabis policy in the United States.
